The persistence of latent HIV proviruses in long-lived CD4 + T cells despite antiretroviral therapy (ART) 1-3 is a major obstacle to viral eradication [4] [5] [6] . Because current candidate latencyreversing agents (LRAs) induce HIV transcription, but fail to clear these cellular reservoirs 7, 8 , new approaches for killing these reactivated latent HIV reservoir cells are urgently needed. HIV latency depends upon the transcriptional quiescence of the integrated provirus and the circumvention of immune defense mechanisms [4] [5] [6] 9 . These defenses include cell-intrinsic innate responses that use pattern-recognition receptors (PRRs) to detect viral pathogens, and that subsequently induce apoptosis of the infected cell 10 . Retinoic acid (RA)-inducible gene I (RIG-I, encoded by DDX58) forms one class of PRRs that mediates apoptosis and the elimination of infected cells after recognition of viral RNA [11] [12] [13] [14] . Here we show that acitretin, an RA derivative approved by the US Food and Drug Administration (FDA), enhances RIG-I signaling ex vivo, increases HIV transcription, and induces preferential apoptosis of HIV-infected cells. These effects are abrogated by DDX58 knockdown. Acitretin also decreases proviral DNA levels in CD4 + T cells from HIV-positive subjects on suppressive ART, an effect that is amplified when combined with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Pharmacological enhancement of an innate cellular-defense network could provide a means by which to eliminate reactivated cells in the latent HIV reservoir.
Despite the suppression of HIV replication by ART, HIV persists as latent proviruses in CD4 + T cells, which enables viral rebound when ART is interrupted [1] [2] [3] . Latent proviruses produce little HIV RNA and protein expression, and they allow immune evasion. Ideal LRAs would reactivate latent proviruses without provoking broad T cell activation, enabling the killing of host cells by either viral cytopathic or immune responses. This is the basis for the 'shock-and-kill' therapeutic approach to eliminate the latent reservoir [4] [5] [6] [7] [8] [9] . In clinical studies, however, SAHA used alone did not deplete reservoir cells, although it did induce viral expression 7 . Moreover, when therapy is delayed, the latent reservoir contains mutations in the virus, which allows for immune escape from cytotoxic T lymphocytes 8 . Consequently, alternative killing strategies are needed 9 .
Cell-intrinsic innate immune defenses against viral infection involve the detection of pathogens through PRRs. RIG-I is a cytosolic PRR [10] [11] [12] [13] [14] [15] that can sense HIV RNA 16 and activate innate antiviral signaling, which leads to the death of infected cells 17 . However, HIV infection impedes RIG-I signaling by sequestration and degradation 18, 19 , and RIG-I protein expression levels are lower individuals with chronic HIV infection than in healthy individuals 20 . RIG-I recognizes full-length HIV RNA more efficiently than short viral transcripts 16 that predominate during latent infection [2] [3] [4] [5] [6] , which thereby limits RIG-I activity in individuals on suppressive ART.
RA induces RIG-I expression 11 , potentially arming an innate immune defense 21, 22 . RA also activates p300 acetyl transferase 23, 24 and could lead to the stimulation of HIV transcription 6 . Acitretin is an FDA-approved RA derivative that has been used to treat patients with HIV who have psoriasis, and the drug is well tolerated 25, 26 . We hypothesized that acitretin could be used to increase HIV transcription and to activate the RIG-I pathway to promote the preferential death of reactivated reservoir cells.
First, we assessed the effects of acitretin on viral expression from ACH-2 cells, a latent-HIV-infected human T cell line 27 . Treatment of ACH-2 cells with acitretin or SAHA for 72 h increased HIV transcription, as compared to treatment with DMSO (Fig. 1a) . The effects of acitretin were partially blocked by curcumin, an inhibitor of p300 (ref. 28) (Fig. 1a) . Acitretin also activated HIV RNA expression in latently infected CD4 + T cells from subjects with HIV on suppressive ART (Fig. 1b) .
The induction of HIV transcription alone may not clear HIV reservoirs [4] [5] [6] [7] [8] [9] . Because acitretin induces RIG-I, and RIG-I signaling can eliminate virally infected cells [10] [11] [12] [13] [14] [15] , we tested the ability of acitretin to promote the clearance of HIV-infected cells in a primary T cell model 29 . We used a single round viral construct, GM-HIV, containing a mutated gag gene (Supplementary Fig. 1 ) to infect unstimulated CD4 + T cells from healthy donors by spinoculation 29, 30 , and then treated cells with acitretin, SAHA, or DMSO. 1 d after treatment, both acitretin and SAHA induced HIV RNA expression (Fig. 1c) . Next, we examined whether the induction of HIV RNA by acitretin was accompanied by p300 induction. Indeed, 48 h after acitretin treatment, p300 expression was increased in GM-HIV infected cells, as compared to that in uninfected cells (Fig. 1d,e) , and the enhancement of p300 association with RNA polymerase II (Pol II) (Fig. 1f,g ) was greater in HIV-infected CEM-T4 cells (a human lymphoblastoid T cell line) 14 than in uninfected cells. Furthermore, after 72 h of treatment, acitretin significantly reduced cellular GM-HIV DNA levels, and acitretin and SAHA in combination reduced cellular GM-HIV DNA to an undetectable level, as measured by real-time PCR (Fig. 1h) .
We next tested whether acitretin reduces HIV DNA levels in samples from subjects with HIV on ART. Treatment of CD4 + T cells from Table 1 ) with acitretin or a combination of acitretin and SAHA for 7 d reduced HIV DNA levels significantly more than did treatment with DMSO, SAHA, or anti-CD3 and anti-CD28 (anti-CD3/anti-CD28) beads (P < 0.05) (Fig. 1i) . The reduction was greatest when acitretin was combined with SAHA. This reduction in HIV DNA concentration by acitretin was not due to the expansion of uninfected cells ( Supplementary  Fig. 2) . Thus, acitretin facilitates the reduction of HIV DNA levels in CD4 + T cells from subjects with HIV in vitro, an effect that has not been seen with any candidate LRAs studied to date. In other models, RIG-I limits viral infection by inducing the apoptosis of infected cells [13] [14] [15] . To determine whether acitretin induces apoptosis in HIV-infected cells, we measured annexin-V staining and caspase-3 activity in GM-HIV-infected and uninfected CD4 + T cells after 72 h of treatment. Acitretin treatment significantly (P < 0.05) increased the percentage of annexin-V + cells (Fig. 2a) and caspase-3 activity in the infected cells, as compared to SAHA and DMSO treatment and uninfected CD4 + T cells (Fig. 2b) , findings that are consistent with reports that the activation of RIG-I induces caspase-3-mediated apoptosis 13 .
To more directly assess whether acitretin induces apoptosis preferentially in HIV-infected cells, and to test for potential synergistic activity with SAHA 31 , cells were infected with GFP-HIV 29 , and infected and uninfected cells were treated with acitretin, SAHA, or both. At 48 h, treatment with acitretin or with acitretin and SAHA in combination both resulted in significantly higher levels of apoptosis in the GFP + cells than in the total cells or the GFP − cells (P < 0.05) (Fig. 2c,d) , which indicates preferential induction of apoptosis in GFP-HIV-infected cells. Furthermore, GFP + cells became significantly less frequent after treatment with acitretin or with acitretin and SAHA combined than with SAHA or DMSO (Fig. 2e) . These results are consistent with a preferential induction of apoptosis in acitretin or acitretin and SAHA-treated HIV-expressing cells that leads to their elimination.
Next, we tested whether acitretin induces apoptosis in CD4 + T cells from subjects positive for HIV on suppressive ART. Acitretin or acitretin and SAHA in combination each stimulated significantly higher levels of apoptosis than did treatment with DMSO, SAHA, or medium. No difference was seen in uninfected cells from healthy controls. Meanwhile, treatment with anti-CD3/anti-CD28 beads and interleukin (IL)-2 led to high levels of apoptosis in cells from both participants positive for HIV and healthy control participants (Fig. 2f,g ). In contrast to treatment with anti-CD3/anti-CD28 beads, acitretin did not upregulate the activation markers CD69 and HLA-DR on CD4 + T cells (Supplementary Fig. 2h ). Kinetic studies showed that the induction of RNA expression occurred later with acitretin than with SAHA, and that acitretin-induced apoptosis was greater for any given HIV-RNA level and time point than in the SAHA or DMSO conditions (Supplementary Fig. 3 ). These results support the conclusion that acitretin preferentially reduces HIV-containing cells by inducing apoptosis.
We examined whether the depletion of cells harboring HIV DNA and the induction of apoptosis by acitretin were dependent on RIG-I signaling. The binding of viral RNA to RIG-I leads to a conformational change in RIG-I (ref. 32 ) that enables binding of mitochondrial antiviral signaling protein (MAVS) 33 and the phosphorylation of interferon-regulatory factor 3 (IRF3) at serine 386 (refs. 34-37), which culminates in type I interferon (IFN) induction and caspase-3 activation [10] [11] [12] [13] [14] [15] . To assess the effects of acitretin on RIG-I expression and signaling, we immunoblotted extracts from HIV-infected cells and uninfected TZM-bl cells-a HeLa cell line containing luciferase and β-galactosidase genes under control of the HIV-1 promoterafter 48 h of treatment with acitretin, or SAHA or DMSO, along with antibodies against RIG-I pathway proteins. Acitretin induces RIG-I in both infected and uninfected cells (Fig. 3a,b) . However, only in HIV-infected cells did acitretin significantly enhance MAVS, IRF3 and phosphoserine 386-IRF3 levels (P < 0.05). Similar patterns were seen in latent GM-HIV-infected CD4 + T cells (Fig. 3c,d) . Acitretin treatment significantly increases the binding of MAVS to RIG-I (ref. 33) in latently HIV-infected CEM-T4 cells, as compared to uninfected cells (Fig. 3) . These observations suggest the initial induction of RIG-I and viral RNA by acitretin, and the subsequent RIG-I sensing of viral RNA [12] [13] [14] [15] 32 promotes RIG-I association with MAVS 38 . RIG-I-induced apoptosis in virus-infected cells depends on the interaction of IRF3 with BCL-2-associated X protein (BAX), which triggers caspasemediated apoptosis 12, 13 . In the presence of acitretin, BAX expression was significantly increased only in HIV-infected cells, as compared to all other conditions, and pretreatment with a BAX inhibitor (V5) peptide 39 , but not with a control peptide, diminished acitretin-induced apoptosis (Fig. 3a-e) . These findings support a role for BAX signaling in acitretin-induced apoptosis 12, 13 .
Next, we measured type I IFN and CXCL10 chemokine production 18,33-37 after 72 h of acitretin treatment in GM-HIV-infected and uninfected primary CD4 + T cells. Acitretin significantly increased IFN-β and CXCL10 secretion in infected cells, as compared to SAHA treatment, but not in uninfected cells (Fig. 3h) . Similarly, IFN-β and CXCL10 levels in day-7 supernatants of T cell cultures from ARTsuppressed subjects with HIV were higher after treatment with acitretin or with acitretin and SAHA combined, as compared to DMSO or SAHA alone (Fig. 3i) . By contrast, no increase in IFN-β or CXCL10 production was detected in acitretin-treated or in acitretin and SAHA-treated cells from healthy volunteers (Fig. 3j) . Acitretin produced dose-related changes in both apoptosis and IFN-β or CXCL10 production in infected cells (Supplementary Fig. 4) . Taken together, these results indicate that acitretin stimulates preferential RIG-I-mediated signaling in HIV-infected cells, which leads not only to apoptosis, but also to type I IFN and chemokine production. The release of IFN and the subsequent activity of npg IFN-stimulated genes might promote the death of some uninfected bystander, as well as infected, cells, which explains why the total number of dying cells is greater than the number of latently infected cells present (Fig. 2a-c,f) . Finally, to establish that the effects of acitretin treatment are mediated through RIG-I, short hairpin RNA (shRNA) was used to inhibit the expression of RIG-I in CEM-T4 cells. DDX58 knockdown abrogated the induction of apoptosis, the production of CXCL10 and IFN-β, and the reduction in HIV DNA by acitretin treatment, but had no impact on the release of HIV virions in this latentinfection model 29 (Fig. 4a-f ). These findings demonstrate the essential role of RIG-I in the observed acitretin effects. Further studies are needed to define the nature of HIV transcripts that bind and activate RIG-I (ref. 10) .
In summary, our data support a model (Fig. 4g) whereby acitretin, at clinically achievable concentrations 40 , increases HIV transcription, induces RIG-I expression, and augments RIG-I signaling, which culminates in the preferential apoptotic death of the reactivated reservoir cells. The addition of LRAs such as SAHA further enhances the effects of acitretin. Thus, one possible approach to inducing the death of reservoir cells could be to use combinations of LRAs and acitretin to preferentially 'shock and kill' CD4 + T cells that harbor HIV. Such an approach might eliminate cells that produce both infectious and noninfectious forms of HIV.
MeTHoDS
Methods and any associated references are available in the online version of the paper. Media and reagents. All T cells and T cell lines were cultured in RPMI 1600 supplemented with penicillin (50 U/ml), streptomycin (50 µg/ml), l-glutamine (2 mM) (all from Life Technologies, Grand Island, NY), and 10% heat-inactivated FCS (FCS) (Sigma-Aldrich, St. Louis, MO). TZM-bl cells were cultured in DMEM supplemented with the same additives as above. During cell culture after treatment or activation, 1 µM indinavir (IDV), 10 µM nevirapine (NVP), and 600 nM raltegravir (RAL) (NIH AIDS Reagent Program) were included to prevent the spreading of HIV infection. Working stocks of acitretin and SAHA were dissolved in DMSO (all from Sigma-Aldrich, St. Louis, MO). Anti-CD3 and anti-CD28 antibody beads (CD3/28) (Life Technologies, Grand Island, NY) were used at 1 bead per cell with human IL-2 (Chiron, Emeryville, CA) at 10 U/ml.
Cell culture and drug treatment. Cell treatment for both primary T cells and cell lines was performed by resuspending cells at 0.5 million cells per ml in complete RPMI (RPMI 1600 supplemented with penicillin (50 U/ml), streptomycin (50 µg/ml), l-glutamine (2 mM) and 10% heat-inactivated FCS (FCS)) with antiretroviral drugs as indicated above. TZM-bl cells were used by plating approximately 2 × 10 5 cells/well of a 24-well tissue culture plate 1 d before infection. This results in approximately 75% cell confluence at the time of infection and further testing. In general, test drugs were used at the following final concentrations: SAHA (350 nM); acitretin (5 µM); equivalent DMSO (final DMSO concentration did not exceed 0.05%) input for negative control. Dose-response studies used acitretin varying from 1-25 µM using the DMSO (final DMSO concentration did not exceed 0.25%), which is equivalent to the 25 µM of acitretin comparator. Cells were maintained in the same drug concentration throughout the duration of experiments, which ranged from 3-7 d. Most assays employed acitretin at a fixed concentration of 5 µM (1,650 ng/ml). RAs are highly lipophilic, and thus, although serum concentrations peak at 500-700 ng/ml, tissue concentrations measured in patients on established therapy reach levels of 16,000 ng/ml or approximately 50 µM (ref. 40) . The concentrations used in the current studies are therefore clinically achievable.
Generation of GM-HIV for single-round HIV infection.
We excised the gag region from pNL4-3 by restriction digest with BssHII (711) and SpeI (1507), subcloning this region into the pcDNA3.1 TOPO TA vector (Life Technologies, Grand Island, NY). Using the Quikchange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), we mutated a region of gag from amino acids 1,404 to 1,432 (Supplementary Fig. 1a) . The sequence-verified mutated gag was recloned into pNL4-3 to make pGM-HIV. To generate GM-HIV capable of only a single round of infection, we co-transfected HEK293T cells (a human kidney cell line (American Type Culture Collection, ATCC), Manassas, VA) with the pGM-HIV clone and a plasmid expressing wild-type gag ( Supplementary Fig. 1a) ; only pGM-HIV with gag-expressing vector can produce p24 into supernatant (Supplementary Fig. 1b) . To confirm the infectivity of GM-HIV, we first infected 0.5 × 10 6 TZM-bl cells with 1 ng of p24 supernatant from pGM-HIV with gag-expressing vector, the same volume of supernatant from pGM-HIV with empty vector, and 1 ng of p24 of HIV-1 (NL-4-3) as a positive control. After 3 d, HIV infectivity was measured using the Bright-Glo Luciferase assay system (Promega) and expressed as relative light units (RLU). Only supernatant from pGM-HIV with gag-expressing vector and HIV-1 (NL4-3) were able to infect TZM-bl cells ( Supplementary  Fig. 1c) . Next, we infected phytohaemagglutinin (PHA)-stimulated 1 × 10 6 CD4 + T cells with 5 ng of p24 in supernatant from pGM-HIV with gag-expressing vector, or an equal volume of supernatant from pGM-HIV with empty vector, by spinoculation at 2,000g for 2 h (ref. 29) . The cells were washed with RPMI three times immediately after infection and once the next day to remove all residual inoculum. Subsequently, the cells were cultured in RPMI with IL-2 (10 U/ml), and then GM-HIV DNA and RNA concentrations were measured in cellular RNA and DNA extracts by real-time PCR at day 1 and day 7. GM-HIV was measurable only in cells infected with supernatant from pGM-HIV with gag-expression vector (Supplementary Fig. 1d ).
Participants with HIV on ART. All participants positive for HIV were on combination ART and had had undetectable plasma viral loads (<50 copies/ml) for at least 1 year (median 5 years) (Supplementary Table 1) . They and the healthy controls were recruited from the San Francisco Veterans Affairs Medical Center (SF-VAMC) Infectious Diseases Clinic to meet the predetermined number of study participants. The study was approved by the UCSF Committee on Human Research and the SF VAMC Human Subject Research subcommittee, and all research participants gave written informed consent.
Isolation and culture of CD4 + T cells from HIV-infected participants and healthy donors. Peripheral blood mononuclear cells (PBMCs) were purified from whole blood (HIV + , on ART) or PBMCs were isolated from leukoreduction filters (healthy donors) by density centrifugation. CD4 + T lymphocytes were enriched by negative selection with the EasySep Human CD4 T cell enrichment kit (Stemcell, Vancouver, BC). The purity of CD4 + T cells was assessed by flow cytometry and was typically >95%. Cells were rested overnight before additional use.
In vitro infection of primary CD4 + T cells with GM-HIV for a primary T cell model of latent HIV infection. Healthy donor CD4 + T cells enriched by negative selection were cultured overnight, and then treated according to the method of Lassen 29 by first infecting the unstimulated, resting CD4 + T cells with GM-HIV (5 ng p24 per 1 × 10 6 cells) by spinoculation at 2,000g for 2 h. Uninfected controls underwent mock spinoculation. The cells were washed with RPMI three times immediately after infection and once the next day to remove all residual inoculum. After the spinoculation of unstimulated CD4 + T cells, the cells were cultured in RPMI for 10 d and integrated to establish latent proviral infection 29 . To confirm that the cells carried latent proviruses, we stimulated the cells with either PHA and IL-2 or anti-CD3/28 beads + IL-2 for 48 h, and then measured cellular GM-HIV RNA. Both PHA with IL-2 (PHA + IL-2) and CD3/28 + IL-2 treatment resulted in significantly increased cellular GM-HIV RNA relative to medium control (Supplementary Fig. 1e ).
Generation of latent GFP-HIV-infected CEM-T4 cells.
A GFP-reporter HIV construct (GFP-HIV) 29 was transfected into HEK293T (ATCC, Manassas, VA) cells to produce GFP-HIV virions. CEM-T4 cells (1 × 10 6 ) were infected with 1,000 pg of p24 for 5 h, and unbound virus was removed by washing the cells three times with RPMI. Subsequently, the cells were cultured in medium with Saquinavir (5 µM) for 10 d to prevent the spreading of infection and to allow for the attrition of productively infected cells 29 . To study whether the cells have latent proviruses, we stimulated the cells with 5 µM acitretin, 350 nM SAHA, or 500 nM prostratin for 72 h, and then harvested supernatant to measure the p24 production. Acitretin, SAHA, and prostratin all significantly increased p24 production, as compared to medium control, which demonstrated that the cells contained proviruses that respond to LRA stimulation (Supplementary Fig. 3a) .
